La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Fortress Biotech Gestione

Gestione criteri di controllo 3/4

Fortress Biotech's Il CEO è Lindsay Rosenwald, nominato in Dec2013, e ha un mandato di 10.67 anni. la retribuzione annua totale è $ 1.12M, composta da 5.6% di stipendio e 94.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 12.68% delle azioni della società, per un valore di $ 5.38M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 10.5 anni e 9.1 anni.

Informazioni chiave

Lindsay Rosenwald

Amministratore delegato

US$1.1m

Compenso totale

Percentuale dello stipendio del CEO	5.6%
Mandato del CEO	10.8yrs
Proprietà del CEO	14.2%
Durata media del management	10.6yrs
Durata media del Consiglio di amministrazione	9.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%

Jul 26

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Dec 29

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Aug 18

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Aug 11

David Jin is the new finance chief of Fortress Biotech

Jul 22

Is Fortress Biotech (NASDAQ:FBIO) Using Debt Sensibly?

Jan 11

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Lindsay Rosenwald rispetto agli utili di Fortress Biotech?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$49m
Mar 31 2024	n/a	n/a	-US$63m
Dec 31 2023	US$1m	US$63k	-US$69m
Sep 30 2023	n/a	n/a	-US$87m
Jun 30 2023	n/a	n/a	-US$104m
Mar 31 2023	n/a	n/a	-US$100m
Dec 31 2022	US$1m	US$63k	-US$95m
Sep 30 2022	n/a	n/a	-US$97m
Jun 30 2022	n/a	n/a	-US$93m
Mar 31 2022	n/a	n/a	-US$74m
Dec 31 2021	US$3m	US$60k	-US$65m
Sep 30 2021	n/a	n/a	-US$38m
Jun 30 2021	n/a	n/a	-US$33m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	US$3m	US$59k	-US$47m
Sep 30 2020	n/a	n/a	-US$57m
Jun 30 2020	n/a	n/a	-US$54m
Mar 31 2020	n/a	n/a	-US$54m
Dec 31 2019	US$1m	US$32k	-US$40m
Sep 30 2019	n/a	n/a	-US$45m
Jun 30 2019	n/a	n/a	-US$51m
Mar 31 2019	n/a	n/a	-US$53m
Dec 31 2018	US$2m	US$31k	-US$73m
Sep 30 2018	n/a	n/a	-US$61m
Jun 30 2018	n/a	n/a	-US$69m
Mar 31 2018	n/a	n/a	-US$72m
Dec 31 2017	US$2m	US$31k	-US$65m

Compensazione vs Mercato: La retribuzione totale di Lindsay ($USD 1.12M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: La retribuzione di Lindsay è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Lindsay Rosenwald (69 yo)

10.8yrs

Mandato

US$1,122,585

Compensazione

Dr. Lindsay Allan Rosenwald, M.D. serves as Director of Urica Therapeutics, Inc. He serves as Director at Caelum Biosciences, Inc. He serves as an Executive Chairman of Journey Medical Corporation since Oc...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Lindsay Rosenwald	Executive Chairman	10.8yrs	US$1.12m	14.24% $ 5.7m
David Jin	CFO & Head of Corporate Development	4.3yrs	US$1.32m	0.031% $ 12.3k
Michael Weiss	Executive Vice Chairman of Strategic Development & Director	10.6yrs	US$962.66k	5.03% $ 2.0m
Samuel Berry	General Counsel & Corporate Secretary	6yrs	Nessun dato	Nessun dato
George Avgerinos	Senior Vice President of Biologics Operations	11.3yrs	US$386.49k	0.16% $ 65.1k

10.6yrs

Durata media

63.5yo

Età media

Gestione esperta: Il team dirigenziale di FBIO è esperto e expertise (durata media dell'incarico 10.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Lindsay Rosenwald	Executive Chairman	14.9yrs	US$1.12m	14.24% $ 5.7m
Michael Weiss	Executive Vice Chairman of Strategic Development & Director	10.8yrs	US$962.66k	5.03% $ 2.0m
Malcolm Hoenlein	Independent Director	10.6yrs	US$45.03k	0.021% $ 8.5k
Stephen Nimer	Scientific Advisor	7.3yrs	Nessun dato	Nessun dato
Dov Klein	Independent Director	9.2yrs	US$120.06k	0.010% $ 4.1k
William Sandborn	Scientific Advisor	7.3yrs	Nessun dato	Nessun dato
J. Lobell	Independent Director	18.3yrs	US$87.57k	0.43% $ 172.4k
Xiaoqin Lu	Director	1.8yrs	US$40.03k	0.012% $ 4.8k
David Elliott	Scientific Advisor	7.3yrs	Nessun dato	Nessun dato
Joel Weinstock	Scientific Advisor	7.3yrs	Nessun dato	Nessun dato
Mark Lowdell	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Jimmie Harvey	Independent Director	15.8yrs	US$67.57k	0.019% $ 7.5k

9.2yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di FBIO sono considerati esperti (durata media dell'incarico 9.1 anni).

Fortress Biotech Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Fortress Biotech, Inc., Annual General Meeting, May 23, 2024

Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc

Executive Chairman recently bought US$119k worth of stock

Fortress Biotech, Inc. Appoints Lucy Lu, M.D., to Its Board of Directors

Executive Chairman recently bought US$68k worth of stock

Insufficient new directors

Recent updates

Consensus revenue estimates fall by 24%

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $6.5 million.

Fortress Biotech, Inc. announced that it has received $1.500001 million in funding

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $128 million.

Consensus revenue estimates increase by 41%

Second quarter 2024 earnings: EPS exceeds analyst expectations

Price target increased by 7.7% to US$14.00

New minor risk - Share price stability

Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%

Fortress Biotech, Inc. announced that it expects to receive $50 million in funding

Consensus EPS estimates fall by 93%, revenue upgraded

New major risk - Negative shareholders equity

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

New major risk - Revenue and earnings growth

Fortress Biotech, Inc., Annual General Meeting, May 23, 2024

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Profitability

Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc

Executive Chairman recently bought US$119k worth of stock

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Fortress Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $11 million.

Price target increased by 27% to US$67.50

Price target decreased by 14% to US$50.00

Forecast to breakeven in 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Fortress Biotech, Inc. has completed a Composite Units Offering.

Fortress Biotech, Inc. has completed a Composite Units Offering.

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg)

New major risk - Share price stability

Fortress Biotech Announces Reverse Stock Split to Regain Compliance

Price target decreased by 8.1% to US$3.55

Consensus revenue estimates fall by 20%

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

New major risk - Financial position

Second quarter 2023 earnings: EPS misses analyst expectations

Forecast breakeven date pushed back to 2025

Consensus revenue estimates increase by 36%

Price target decreased by 13% to US$4.34

Consensus revenue estimates fall by 40%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fortress Biotech Receives Second 180-Calendar Day Grace Period from Nasdaq to Regain Compliance with the Nasdaq Listing Rule 5550(a)(2)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased by 16% to US$5.10

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $13.896816 million.

Fortress Biotech, Inc. Appoints Lucy Lu, M.D., to Its Board of Directors

Price target decreased to US$5.92

Executive Chairman recently bought US$68k worth of stock

No longer forecast to breakeven

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Insufficient new directors

Fortress Biotech Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Executive Chairman recently bought US$70k worth of stock

Urica Therapeutics, Inc Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer

Consensus revenue estimates fall by 13%

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Fortress Biotech, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Fortress Biotech Inc. Appoints David Jin as Chief Financial Officer

David Jin is the new finance chief of Fortress Biotech

Price target decreased to US$6.10

Fortress Biotech, Inc.(NasdaqCM:FBIO) dropped from Russell 2000 Dynamic Index

Fortress Biotech, Inc.'s Subsidiary UR-1 Therapeutics, Inc. Doses First Patient in a Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

First quarter 2022 earnings: EPS and revenues exceed analyst expectations